Literature DB >> 6132990

Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog.

B I Hirschowitz, J Fong, E Molina.   

Abstract

To characterize and quantitate pathways of stimulation of gastric secretion via vagal excitation induced by 2-deoxy-D-glucose, we used graded doses of the two muscarinic antagonists, atropine and pirenzepine. Studies were performed in four conscious gastric fistula dogs with antral vagotomy to eliminate the gastrin release component of the vagal response. To further localize the site of action of the antagonists, both were tested against bethanechol, which stimulates secretion at postganglionic sites. Acid and pepsin secretion stimulated by either bethanechol or the vagus were inhibited in a dose-responsive manner by both atropine and pirenzepine, which displayed similar potencies. These data indicate that: 1) the vagus acts on the gastric fundus solely via muscarinic receptors; 2) the muscarinic receptors controlling gastric secretion are of the high-affinity (M-1) subtype; and 3) the vagus is very sensitive to atropine with D50 less than 1.4 nmol/kg. Heart rate was increased up to 120 beats/min above the resting rate by atropine; half-maximal increase was calculated to occur at 10 nmol/kg (ED50). Pirenzepine had a much less potent effect on the heart; the ED50 was 200 to 300 times greater than that for atropine. These data indicate that heart rate is affected by a mechanism acting via a muscarinic receptor pathway that has a low affinity for pirenzepine (M-2 receptor subtype).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132990

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Muscarinic receptor subtypes: implications for lung disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1989-03       Impact factor: 9.139

2.  Inhibitory effects of pirenzepine on cholecystokinin and secretin stimulation on exocrine and endocrine rat pancreas.

Authors:  M Otsuki; Y Okabayashi; T Nakamura; M Fujii; T Oka; S Tani; S Baba
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

3.  Subtypes of muscarinic receptors in canine pancreatic secretion in vivo and in vitro.

Authors:  S J Konturek; J Jaworek; J Tasler; M Cieszkowski; N Yanaihara
Journal:  Int J Pancreatol       Date:  1987-02

Review 4.  Recent advances in the treatment of duodenal ulcer disease. A surgical perspective.

Authors:  M W Mulholland; H T Debas
Journal:  West J Med       Date:  1987-09

5.  Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls.

Authors:  B I Hirschowitz; J Groarke
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

6.  Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist.

Authors:  H Hinrichsen; A Halabi; G Fuhrmann; W Kirch
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

Review 7.  Pepsinogen.

Authors:  B I Hirschowitz
Journal:  Postgrad Med J       Date:  1984-11       Impact factor: 2.401

8.  Molecular characterization of muscarinic receptor subtypes in bovine cerebral cortex by radiation inactivation and molecular exclusion h.p.l.c.

Authors:  O Shirakawa; C Tanaka
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

9.  Effects of very low doses of atropine on basal acid and pepsin secretion, gastrin, and heart rate in normals and DU.

Authors:  B I Hirschowitz; E Molina; L Ou Tim; C Helman
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

10.  Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy.

Authors:  H F Pitschner; A Wellstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.